Ovid Therapeutics חובות 2024

מה עושה Ovid Therapeutics?

Ovid Therapeutics Inc. is a US biopharmaceutical company focused on developing targeted therapies for rare neurological disorders. The company was founded in 2014 and is based in New York. Ovid Therapeutics aims to develop a new class of therapeutics based on regulating the GABA receptor in the brain. GABA is a neurotransmitter responsible for inhibiting neuronal activity in the brain. By modulating the GABA receptor through pharmacological interventions, Ovid Therapeutics hopes to achieve a neuroprotective effect and treat a variety of rare neurological disorders. The company's therapies aim to alleviate symptoms of these diseases and improve brain function by targeting the behavior of GABA receptors. Ovid Therapeutics specializes in researching and developing drugs for three specific conditions: Angelman syndrome, Fragile X syndrome, and tuberous sclerosis complex. Ovid Therapeutics' business model is based on a combination of innovative sciences developed in the start-up model and a focus on strategic partnerships and collaborations with other pharmaceutical and biotech companies. The company's core business involves the clinical development of therapeutic options. Ovid Therapeutics follows a dual-track strategy, developing its own pipeline while also pursuing partnerships with other pharmaceutical companies to secure additional funding and research capabilities. Ovid Therapeutics has an extensive portfolio of preclinical and clinical drugs targeting rare neurological disorders with different drug classes and mechanisms of action. In recent years, Ovid Therapeutics has gained an excellent reputation in the scientific community and won numerous awards. Recently, the company was also recognized as "One to Watch" at the second annual BioCentury's "Beyond Borders." Gaboxadol is the first drug brought to market by Ovid Therapeutics. Gaboxadol is a modulator of the GABAb receptor that has shown excellent results in studies for treating Angelman syndrome. Based on such results, the company is now focused on further developing therapeutic options and conducting more research in the field of rare neurological disorders. Ovid Therapeutics has directed its efforts towards addressing the needs of a patient population that has limited treatment options due to rare neurological disorders. Based on the extensive research results the company has already achieved, its goal is to lay the groundwork for developing novel therapeutics and significantly improving the quality of life for affected patients. Ovid Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.